Understand the source comparison
FOXO4-DRI Support Anti-Aging Stack: Comparison Across Senolytic Compounds
Choosing the right senolytic for an anti-aging stack depends on mechanism, tissue selectivity, and evidence base. FOXO4-DRI competes primarily with dasatinib + quercetin (D+Q) and high-dose fisetin. The three most studied senolytic interventions in preclinical
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Choosing the right senolytic for an anti-aging stack depends on mechanism, tissue selectivity, and evidence base. FOXO4-DRI competes primarily with dasatinib + quercetin (D+Q) and high-dose fisetin. The three most studied senolytic interventions in preclinical and early human trials.
- FOXO4-DRI
- Disrupts FOXO4-p53 interaction, restoring p53-mediated apoptosis in senescent cells
- Broad tissue distribution; strongest evidence in kidney, liver, and adipose
- Preclinical (mouse models); demonstrated functional improvement in aged mice (2017 Cell paper)
- 3–5 consecutive days per month; subcutaneous peptide administration
- Most mechanistically specific senolytic; requires peptide handling and reconstitution; suitable for structured research protocols
- Dasatinib + Quercetin (D+Q)
- Dasatinib inhibits tyrosine kinases; quercetin inhibits anti-apoptotic BCL-2 family proteins
- Effective across multiple tissue types including adipose, bone, and vascular tissue
- Human pilot trials (Mayo Clinic); Phase 1 safety data in idiopathic pulmonary fibrosis and diabetic kidney disease
- 3 consecutive days per month; oral administration
- Most studied senolytic in human trials; oral administration simplifies logistics; D+Q combination is synergistic but less selective than FOXO4-DRI
- Fisetin (High-Dose)
- Inhibits anti-apoptotic pathways including PI3K/AKT and promotes senescent cell apoptosis
- Strong CNS penetration; evidence for brain-specific senolysis and neuroprotection
- Preclinical (mouse models); small human pilot (Mayo Clinic, 2019); ongoing trials in Alzheimer's and frailty
- 2–3 consecutive days per month at 1000–1500mg oral
- Best option for CNS-targeted senolysis; oral bioavailability requires high doses; less selective than FOXO4-DRI but broader supplement availability
- Rapamycin (mTOR inhibitor)
- Inhibits mTOR signaling; induces autophagy and reduces senescent cell accumulation indirectly
- Systemic; affects protein synthesis, autophagy, and immune function
- Extensive clinical use as immunosuppressant; longevity studies in mice; human trials for aging underway
- Weekly dosing (5–8mg) or intermittent cycles
- Not a direct senolytic but reduces senescent cell burden through autophagy; immunosuppressive effects require medical oversight; complements FOXO4-DRI